Seek Returns

RVTY vs. VRTX: Revvity vs. Vertex Pharmaceuticals Stock Comparison

How do Revvity (RVTY) and Vertex Pharmaceuticals (VRTX) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Revvity (RVTY) and Vertex Pharmaceuticals (VRTX) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but RVTY is classified in Life Sciences Tools & Services while VRTX is classified in Biotechnology.

Company profile comparison for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
Profile ItemRVTYVRTX
NameRevvity Inc.Vertex Pharmaceuticals Incorporated Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesBiotechnology
GICS Sub-IndustryLife Sciences Tools & ServicesBiotechnology
Market Capitalization17.31 billion USD138.71 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateFebruary 21, 1973July 24, 1991
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

RVTY
VRTX
GSPC
Loading price history…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Total Return (1Y)76.75%34.89%
Total Return (3Y, Annualized)24.22%14.44%
Total Return (5Y, Annualized)-1.48%23.65%

Risk Profile

Drawdown History

RVTY
VRTX
GSPC
Loading price history…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Volatility (1Y, Annualized)40.22%29.73%
Beta (5Y)1.070.29
Max Drawdown (5Y)-59.01%-29.07%
Avg. Volume (3M)1.89M1.25M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
RVTY and VRTX are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Sharpe Ratio (1Y)1.801.03
Sortino Ratio (1Y)2.901.68

Profitability

ROE (TTM)

Vertex Pharmaceuticals (VRTX) at 20.80% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for VRTX.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max
109.18%
Q3
6.23%
RVTY
3.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.80%

Max
109.18%
VRTX
20.80%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Vertex Pharmaceuticals (VRTX) at 30.70% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max
18.05%
RVTY
8.61%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.70%

VRTX
30.70%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Revvity (RVTY) at 17.06% and Vertex Pharmaceuticals (VRTX) at 35.57% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max
83.12%
RVTY
17.06%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.57%

Max
83.12%
VRTX
35.57%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
ROE (TTM)3.45%20.80%
ROA (TTM)2.54%10.62%
Net Margin (TTM)8.61%30.70%
Operating Margin (TTM)17.06%35.57%
Gross Margin (TTM)55.91%54.81%

Growth

Revenue Growth

Both Revvity (RVTY) at 3.67% and Vertex Pharmaceuticals (VRTX) at 8.90% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Revvity (RVTY) reports EPS growth of -5.91%, ranked against its industry; Vertex Pharmaceuticals (VRTX) has no EPS growth figure this period.

Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Revenue Growth (YoY)3.67%8.90%
Revenue Growth (3Y CAGR)-4.82%10.35%
EPS Growth (YoY)-5.91%--
EPS Growth (3Y CAGR)-23.26%6.12%

Financial Strength

Current Ratio (MRQ)

Revvity (RVTY) at 2.65 keeps current ratio within its industry’s typical mid-range, while Vertex Pharmaceuticals (VRTX) at 2.34 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for VRTX.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max
25.13
Q3
12.13
Median
5.52
RVTY
2.65
Q1
2.47
Min
0.10

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.34

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
VRTX
2.34
Min
0.10
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Revvity (RVTY) at 0.38 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max
1.42
Q3
0.65
RVTY
0.38
Median
0.15
Q1
0.02
Min
0.00

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.31

Max
1.42
Q3
0.65
VRTX
0.31
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Current Ratio (MRQ)2.652.34
Debt / Equity (MRQ)0.380.31
Net Debt / EBITDA2.430.03

Dividends

Dividend Yield (TTM)

Vertex Pharmaceuticals (VRTX) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a yield of 0.19%, ranking against industry peers normally.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY
0.19%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

VRTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Vertex Pharmaceuticals (VRTX) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Revvity (RVTY) reports a payout of 13.40%, ranking against industry peers normally.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY
13.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

VRTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
Dividend Yield (TTM)0.19%0.00%
Dividend Payout Ratio (TTM)13.40%0.00%

Valuation

P/E Ratio (TTM)

Vertex Pharmaceuticals (VRTX) at 35.21 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max
85.34
RVTY
68.94
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.21

Max
85.34
Q3
43.46
VRTX
35.21
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Revvity (RVTY) at 5.88 and Vertex Pharmaceuticals (VRTX) at 10.71 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max
58.18
Q3
25.77
Median
7.30
RVTY
5.88
Q1
3.01
Min
0.01

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.71

Max
58.18
Q3
25.77
VRTX
10.71
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Revvity (RVTY) at 2.39 is valued about in line with its industry on P/B ratio, while Vertex Pharmaceuticals (VRTX) at 6.63 carries an above-peer premium to book — VRTX is pricier on assets.

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max
13.53
Q3
6.54
Median
3.25
RVTY
2.39
Q1
1.69
Min
-5.59

VRTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.63

Max
13.53
VRTX
6.63
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Revvity (RVTY) vs. Vertex Pharmaceuticals (VRTX): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Revvity (RVTY) and Vertex Pharmaceuticals (VRTX)
MetricRVTYVRTX
P/E Ratio (TTM)68.9435.21
P/S Ratio (TTM)5.8810.71
P/B Ratio (MRQ)2.396.63
Free Cash Flow Yield (TTM)3.62%1.69%